Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

NCT01802866 is registered in ClinicalTrials.gov with Kubota Vision Inc. as lead sponsor.

NCT NCT01802866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01802866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Lead sponsor
Kubota Vision Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2013
Completion date
May 31, 2016
Enrollment
508 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy